134 related articles for article (PubMed ID: 33370727)
1. Meta-Analysis of Prognostic Factors for Recurrence of Resected Well-Differentiated Pancreatic Neuroendocrine Tumors.
Li Y; Fan G; Yu F; Tian C; Tan H
Neuroendocrinology; 2021; 111(12):1231-1237. PubMed ID: 33370727
[TBL] [Abstract][Full Text] [Related]
2. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
[TBL] [Abstract][Full Text] [Related]
3. A meta-analysis of Prognostic factor of Pancreatic neuroendocrine neoplasms.
Gao Y; Gao H; Wang G; Yin L; Xu W; Peng Y; Wu J; Jiang K; Miao Y
Sci Rep; 2018 May; 8(1):7271. PubMed ID: 29739948
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Role of Examined and Positive Lymph Nodes after Distal Pancreatectomy for Non-Functioning Neuroendocrine Neoplasms.
Guarneri G; de Mestier L; Landoni L; Partelli S; Gaujoux S; Andreasi V; Nessi C; Dokmak S; Fontana M; Dousset B; Ruszniewski P; Bassi C; Falconi M; Sauvanet A
Neuroendocrinology; 2021; 111(8):728-738. PubMed ID: 32585667
[TBL] [Abstract][Full Text] [Related]
5. Do morphologic characteristics play a role in nodal metastatic progression of well-differentiated pancreatic neuroendocrine tumors?
Ugras N; Hasdemir S; Yerci Ö; Taşar P; Dündar HZ; Macunluoğlu AC
Tumori; 2021 Feb; 107(1):80-85. PubMed ID: 32705937
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.
Broadbent R; Wheatley R; Stajer S; Jacobs T; Lamarca A; Hubner RA; Valle JW; Amir E; McNamara MG
Cancer Treat Rev; 2021 Dec; 101():102299. PubMed ID: 34662810
[TBL] [Abstract][Full Text] [Related]
7. Prognostic predictors for recurrence following curative resection in grade I/II pancreatic neuroendocrine tumours.
Chopde A; Gupta A; Chaudhari V; Parghane R; Basu S; Ostwal V; Ramaswamy A; Puranik A; Shrikhande SV; Bhandare MS
Langenbecks Arch Surg; 2023 May; 408(1):204. PubMed ID: 37212896
[TBL] [Abstract][Full Text] [Related]
8. Analysis of risk factors affecting the prognosis of pancreatic neuroendocrine tumors.
Tao M; Yuan C; Xiu D; Shi X; Tao L; Ma Z; Jiang B; Zhang Z; Zhang L; Wang H
Chin Med J (Engl); 2014; 127(16):2924-8. PubMed ID: 25131229
[TBL] [Abstract][Full Text] [Related]
9. A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors.
Wang WQ; Zhang WH; Gao HL; Huang D; Xu HX; Li S; Li TJ; Xu SS; Li H; Long J; Ye LY; Wu CT; Han X; Wang XH; Liu L; Yu XJ
J Gastroenterol; 2021 Apr; 56(4):395-405. PubMed ID: 33742253
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.
Zhang P; Li YL; Qiu XD; Luo J; Shi YF; Sun YL; Su F; Qi ZR; Tan HY
World J Surg Oncol; 2019 Apr; 17(1):66. PubMed ID: 30975157
[TBL] [Abstract][Full Text] [Related]
11. Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence.
Merola E; Pascher A; Rinke A; Bartsch DK; Zerbi A; Nappo G; Carnaghi C; Ciola M; McNamara MG; Zandee W; Bertani E; Marcucci S; Modica R; Grützmann R; Fazio N; de Herder W; Valle JW; Gress TM; Fave GD; de Pretis G; Perren A; Wiedenmann B; Pavel ME
Ann Surg Oncol; 2022 Sep; 29(9):5568-5577. PubMed ID: 35583694
[TBL] [Abstract][Full Text] [Related]
12. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
[TBL] [Abstract][Full Text] [Related]
13. Venous invasion and lymphatic invasion are correlated with the postoperative prognosis of pancreatic neuroendocrine neoplasm.
Kiritani S; Arita J; Mihara Y; Nagata R; Ichida A; Kawaguchi Y; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K
Surgery; 2023 Feb; 173(2):365-372. PubMed ID: 36123176
[TBL] [Abstract][Full Text] [Related]
14. Gastric neuroendocrine neoplasms type 1: A systematic review and meta-analysis.
Tsolakis AV; Ragkousi A; Vujasinovic M; Kaltsas G; Daskalakis K
World J Gastroenterol; 2019 Sep; 25(35):5376-5387. PubMed ID: 31558880
[TBL] [Abstract][Full Text] [Related]
15. Are Cystic Pancreatic Neuroendocrine Tumors an Indolent Entity Results from a Single-Center Surgical Series.
Paiella S; Marchegiani G; Miotto M; Malpaga A; Impellizzeri H; Montagnini G; Pollini T; Nessi C; Butturini G; Capelli P; Posenato I; Scarpa A; D'Onofrio M; De Robertis R; Cingarlini S; Boninsegna L; Bassi C; Salvia R; Landoni L
Neuroendocrinology; 2018; 106(3):234-241. PubMed ID: 28586782
[TBL] [Abstract][Full Text] [Related]
16. Significance of Lymph Node Metastasis in Resectable Well-differentiated Pancreatic Neuroendocrine Tumor.
Harimoto N; Hoshino K; Muranushi R; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Araki K; Hosouchi Y; Suzuki H; Arakawa K; Hirai K; Fukazawa T; Ikota H; Shirabe K
Pancreas; 2019 Aug; 48(7):943-947. PubMed ID: 31268980
[TBL] [Abstract][Full Text] [Related]
17. Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence.
Nanno Y; Toyama H; Otani K; Asari S; Goto T; Terai S; Ajiki T; Zen Y; Fukumoto T; Ku Y
Pancreatology; 2016; 16(5):882-7. PubMed ID: 27350059
[TBL] [Abstract][Full Text] [Related]
18. O-positive blood type is associated with prolonged recurrence-free survival following curative resection of pancreatic neuroendocrine tumors.
De Rycke O; Védie AL; Guarneri G; Nin F; De Flori C; Hentic O; Idri S; Sauvanet A; Rebours V; Cros J; Couvelard A; Ruszniewski P; de Mestier L
Pancreatology; 2020 Dec; 20(8):1718-1722. PubMed ID: 33032924
[TBL] [Abstract][Full Text] [Related]
19. A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors.
Genç CG; Jilesen AP; Partelli S; Falconi M; Muffatti F; van Kemenade FJ; van Eeden S; Verheij J; van Dieren S; van Eijck CHJ; Nieveen van Dijkum EJM
Ann Surg; 2018 Jun; 267(6):1148-1154. PubMed ID: 28594340
[TBL] [Abstract][Full Text] [Related]
20. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
